Compounded Medication – Prescription Only

This product is a compounded orally disintegrating tablet (ODT) formulation containing tirzepatide and is dispensed only pursuant to a valid prescription issued by a licensed healthcare provider. Tirzepatide is a synthetic peptide with activity at glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. In compounding practice, tirzepatide formulations may be prescribed when a provider determines that individualized concentration, formulation, or dosing considerations are clinically appropriate for a specific patient. This product is not available for self-selection and may only be dispensed following provider authorization.

Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). The FDA does not evaluate compounded formulations for safety, effectiveness, or quality. Compounding is performed by a state-licensed pharmacy pursuant to a patient-specific prescription. This page provides general, non-therapeutic information for educational and compliance purposes only. It does not describe intended use, therapeutic benefit, weight-related outcomes, glycemic effects, appetite effects, or expected clinical results.

General Scientific Information (Non-Therapeutic)

Tirzepatide has been examined in scientific and clinical research for its molecular structure and classification as a dual GIP/GLP-1 receptor agonist under controlled research conditions. Descriptions of receptor interactions or biochemical characteristics are provided solely for general scientific context. No claims are made regarding safety, effectiveness, metabolic outcomes, weight change, glycemic control, or suitability for any particular condition.

Formulation Considerations

Compounded formulations of tirzepatide may be prepared in different concentrations or delivery formats as determined by the prescribing healthcare provider. These variations reflect formulation preferences or individual patient considerations and do not alter the regulatory status of the compounded medication. Differences in formulation do not imply enhanced effectiveness, mitigation of side effects, or altered clinical outcomes.

Contraindications

Tirzepatide ODT should not be used in individuals who have a known hypersensitivity or allergy to tirzepatide or any component of the compounded formulation; have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2); have experienced prior serious adverse reactions to GLP-1 receptor agonists or related peptides; or have other conditions in which incretin-based therapy is contraindicated as determined by the prescribing healthcare provider. Use in pregnant or breastfeeding individuals should occur only if a licensed healthcare provider determines that potential risks and benefits have been carefully evaluated.

Warnings and Precautions

Dual incretin receptor agonists may be associated with gastrointestinal and other systemic effects. Caution is advised in individuals with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, or renal impairment. This orally disintegrating tablet should be used only as prescribed by a licensed healthcare provider. Patients should inform their healthcare provider of all medical conditions, medications, and supplements prior to receiving this compounded formulation.

Potential Side Effects

Reported side effects associated with incretin-based formulations may include nausea, vomiting, diarrhea, constipation, abdominal discomfort, headache, dizziness, or fatigue. Serious adverse reactions are uncommon but may occur. Patients should seek immediate medical attention if they experience severe abdominal pain, symptoms suggestive of pancreatitis, signs of a severe allergic reaction, or other unexpected systemic symptoms.